149 related articles for article (PubMed ID: 11369016)
1. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus.
Niemeijer-Kanters SD; Dallinga-Thie GM; de Ruijter-Heijstek FC; Algra A; Erkelens DW; Banga JD; Jansen H
Atherosclerosis; 2001 May; 156(1):209-16. PubMed ID: 11369016
[TBL] [Abstract][Full Text] [Related]
2. Intensive lipid-lowering strategy in patients with diabetes mellitus.
Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
[TBL] [Abstract][Full Text] [Related]
3. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
4. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
[TBL] [Abstract][Full Text] [Related]
5. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
6. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
7. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
8. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
Lemieux I; Laperrière L; Dzavik V; Tremblay G; Bourgeois J; Després JP
Atherosclerosis; 2002 Jun; 162(2):363-71. PubMed ID: 11996956
[TBL] [Abstract][Full Text] [Related]
9. Ability of non-high-density lipoprotein cholesterol and calculated intermediate-density lipoprotein to identify nontraditional lipoprotein subclass risk factors in dialysis patients.
Belani SS; Goldberg AC; Coyne DW
Am J Kidney Dis; 2004 Feb; 43(2):320-9. PubMed ID: 14750098
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.
Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR
Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318
[TBL] [Abstract][Full Text] [Related]
11. Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes.
Koba S; Hirano T; Yoshino G; Sakai K; Sakaue T; Adachi M; Katagiri T
Atherosclerosis; 2002 Jan; 160(1):249-56. PubMed ID: 11755944
[TBL] [Abstract][Full Text] [Related]
12. LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?
Taskinen MR
Diabetes Res Clin Pract; 2003 Jul; 61 Suppl 1():S19-26. PubMed ID: 12880691
[TBL] [Abstract][Full Text] [Related]
13. Low-density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women.
Maki KC; Davidson MH; Cyrowski MS; Maki AC; Marx P
J Am Coll Nutr; 2000 Feb; 19(1):23-30. PubMed ID: 10682872
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control.
Bavirti S; Ghanaat F; Tayek JA
Endocr Pract; 2003; 9(6):487-93. PubMed ID: 14715475
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
16. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels.
Halle M; Berg A; Baumstark MW; König D; Huonker M; Keul Joseph
Atherosclerosis; 1999 Mar; 143(1):185-92. PubMed ID: 10208494
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
18. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
Tokuno A; Hirano T; Hayashi T; Mori Y; Yamamoto T; Nagashima M; Shiraishi Y; Ito Y; Adachi M
J Atheroscler Thromb; 2007 Jun; 14(3):128-32. PubMed ID: 17587764
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Lazzarini V; Fruzzetti F; Carmina E
J Clin Endocrinol Metab; 2007 Jan; 92(1):186-9. PubMed ID: 17062762
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy.
Hirano T; Naito H; Kurokawa M; Ebara T; Nagano S; Adachi M; Yoshino G
Atherosclerosis; 1996 Jun; 123(1-2):57-72. PubMed ID: 8782837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
